In a bid to build on its growing immuno-oncology presence, Gilead Sciences has formed a 10-year partnership with Arcus Biosciences to jointly develop and commercialise all current and future therapeutic product candidates in Arcus’s pipeline in exchange for US$375 M upfront. With the deal, Gilead gains access to Arcus’s anti-PD-1 antibody, zimberelimab, and opt-in rights to the company’s other clinical candidates. The deal follows similar terms to the paradigm-shifting deal Gilead signed with Galapagos in July 2019, and grants Arcus the opportunity to grow independently while drawing on the resources, capital and expertise of Gilead.